Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life.

Montemagni C, Frieri T, Rocca P.

Neuropsychiatr Dis Treat. 2016 Apr 19;12:917-29. doi: 10.2147/NDT.S88632. Review.

2.

Recommendations for the optimal care of patients with recent-onset psychosis in the Asia-Pacific region.

Lo TL, Warden M, He Y, Si T, Kalyanasundaram S, Thirunavukarasu M, Amir N, Hatim A, Bautista T, Lee C, Emsley R, Olivares J, Yang YK, Kongsakon R, Castle D.

Asia Pac Psychiatry. 2016 Jun;8(2):154-71. doi: 10.1111/appy.12234.

3.

Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?

Niolu C, Bianciardi E, Di Lorenzo G, Marchetta C, Barone Y, Sterbini N, Ribolsi M, Reggiardo G, Siracusano A.

Ther Adv Psychopharmacol. 2015 Oct;5(5):278-88. doi: 10.1177/2045125315596897.

4.

Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.

Stevens GL, Dawson G, Zummo J.

Early Interv Psychiatry. 2016 Oct;10(5):365-77. doi: 10.1111/eip.12278. Review.

5.

The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V.

Ther Adv Psychopharmacol. 2014 Oct;4(5):198-219. doi: 10.1177/2045125314540297. Review.

6.

IVIVC from Long Acting Olanzapine Microspheres.

D'Souza S, Faraj JA, Giovagnoli S, Deluca PP.

Int J Biomater. 2014;2014:407065. doi: 10.1155/2014/407065.

7.

Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.

Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L.

BMC Psychiatry. 2013 Dec 20;13:340. doi: 10.1186/1471-244X-13-340.

8.

Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).

Smeraldi E, Cavallaro R, Folnegović-Šmalc V, Bidzan L, Emin Ceylan M, Schreiner A.

Ther Adv Psychopharmacol. 2013 Aug;3(4):191-9. doi: 10.1177/2045125313479127.

9.

Patients' and clinicians' attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis.

Kirschner M, Theodoridou A, Fusar-Poli P, Kaiser S, Jäger M.

Ther Adv Psychopharmacol. 2013 Apr;3(2):89-99. doi: 10.1177/2045125312464106.

10.

Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review.

Olivares JM, Sermon J, Hemels M, Schreiner A.

Ann Gen Psychiatry. 2013 Oct 23;12(1):32. doi: 10.1186/1744-859X-12-32.

11.

Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial.

Bossie CA, Fu DJ, Sliwa JK, Ma YW, Alphs L.

Ther Adv Psychopharmacol. 2011 Aug;1(4):111-24. doi: 10.1177/2045125311413006. Erratum in: Ther Adv Psychopharmacol. 2011 Oct;1(5):163.

12.

Long-acting Injectable Antipsychotics in First-episode Schizophrenia.

Jeong HG, Lee MS.

Clin Psychopharmacol Neurosci. 2013 Apr;11(1):1-6. doi: 10.9758/cpn.2013.11.1.1.

13.

Second-generation antipsychotic discontinuation in first episode psychosis: an updated review.

Miller BJ, Bodenheimer C, Crittenden K.

Clin Psychopharmacol Neurosci. 2011 Aug;9(2):45-53. doi: 10.9758/cpn.2011.9.2.45.

14.

Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons.

Kim B, Lee SH, Yang YK, Park JI, Chung YC.

Schizophr Res Treatment. 2012;2012:560836. doi: 10.1155/2012/560836.

16.

Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia.

Viala A, Cornic F, Vacheron MN.

Schizophr Res Treatment. 2012;2012:368687. doi: 10.1155/2012/368687.

17.

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia.

Sliwa JK, Bossie CA, Fu DJ, Turkoz I, Alphs L.

Neuropsychiatr Dis Treat. 2012;8:375-85. doi: 10.2147/NDT.S32581.

18.
19.

Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results.

Macfadden W, DeSouza C, Crivera C, Kozma CM, Dirani RD, Mao L, Rodriguez SC.

BMC Psychiatry. 2011 Oct 14;11:167. doi: 10.1186/1471-244X-11-167.

20.

Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia.

Subotnik KL, Nuechterlein KH, Ventura J, Gitlin MJ, Marder S, Mintz J, Hellemann GS, Thornton LA, Singh IR.

Am J Psychiatry. 2011 Mar;168(3):286-92. doi: 10.1176/appi.ajp.2010.09010087.

Items per page

Supplemental Content

Support Center